Tandem Capital Management Corp ADV raised its position in Boston Scientific Co. (NYSE:BSX – Free Report) by 0.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 58,351 shares of the medical equipment provider’s stock after buying an additional 485 shares during the period. Boston Scientific makes up about 2.7% of Tandem Capital Management Corp ADV’s holdings, making the stock its 7th biggest holding. Tandem Capital Management Corp ADV’s holdings in Boston Scientific were worth $4,890,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of the business. BI Asset Management Fondsmaeglerselskab A S boosted its stake in shares of Boston Scientific by 225.6% during the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 105,671 shares of the medical equipment provider’s stock valued at $7,237,000 after buying an additional 73,219 shares during the last quarter. BDF Gestion acquired a new position in Boston Scientific during the 2nd quarter worth $3,570,000. LRI Investments LLC bought a new stake in shares of Boston Scientific in the 1st quarter worth about $139,000. Cetera Advisor Networks LLC raised its stake in shares of Boston Scientific by 11.8% in the 1st quarter. Cetera Advisor Networks LLC now owns 201,426 shares of the medical equipment provider’s stock valued at $13,796,000 after purchasing an additional 21,252 shares in the last quarter. Finally, Brookstone Capital Management lifted its position in shares of Boston Scientific by 389.1% during the second quarter. Brookstone Capital Management now owns 69,945 shares of the medical equipment provider’s stock worth $5,414,000 after purchasing an additional 55,645 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the firm’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $85.00, for a total transaction of $11,264,795.00. Following the completion of the sale, the executive vice president now directly owns 160,467 shares in the company, valued at approximately $13,639,695. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $81.70, for a total transaction of $570,511.10. Following the completion of the sale, the executive vice president now directly owns 37,468 shares in the company, valued at approximately $3,061,135.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 132,527 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $85.00, for a total value of $11,264,795.00. Following the completion of the transaction, the executive vice president now directly owns 160,467 shares in the company, valued at approximately $13,639,695. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 316,253 shares of company stock worth $26,714,298 over the last quarter. Corporate insiders own 0.50% of the company’s stock.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Analysis on Boston Scientific
Boston Scientific Price Performance
Boston Scientific stock traded down $1.35 during mid-day trading on Friday, hitting $83.75. The company’s stock had a trading volume of 657,858 shares, compared to its average volume of 6,019,053. The stock has a market capitalization of $122.87 billion, a P/E ratio of 71.52, a P/E/G ratio of 2.87 and a beta of 0.80. Boston Scientific Co. has a twelve month low of $49.15 and a twelve month high of $88.79. The stock’s fifty day moving average price is $83.19 and its two-hundred day moving average price is $77.57. The company has a quick ratio of 1.14, a current ratio of 1.61 and a debt-to-equity ratio of 0.44.
Boston Scientific (NYSE:BSX – Get Free Report) last posted its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.04. Boston Scientific had a return on equity of 16.59% and a net margin of 12.00%. The firm had revenue of $4.21 billion for the quarter, compared to the consensus estimate of $4.04 billion. During the same quarter in the previous year, the company earned $0.50 EPS. The business’s revenue for the quarter was up 19.3% compared to the same quarter last year. Research analysts forecast that Boston Scientific Co. will post 2.4 earnings per share for the current year.
Boston Scientific Company Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Recommended Stories
- Five stocks we like better than Boston Scientific
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Texas Roadhouse Stock Steering for New Highs This Year
- Top Stocks Investing in 5G Technology
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Top Biotech Stocks: Exploring Innovation Opportunities
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.